Antibody Development & Production Conference
2024
Hilton Boston/Woburn, 2 Forbes Rd, Woburn, MA 01801
March 18-20, 2024
Register now
Apply to Speak
ADP Conference Boston 2024

The Antibody Development and Production Conference (ADP-2024) is a leading event for researchers, scientists, and industry professionals in antibody therapeutics. Our primary objective is to facilitate collaboration, innovation, and knowledge sharing to enhance the development and production of effective antibody-based therapies. The conference focuses on practical applications and real-world case studies, covering a wide range of topics such as antibody discovery, engineering, expression, purification, formulation, analytics, and clinical development.​

The conference brings together experts from academia, industry, and regulatory agencies, fostering a collaborative and inclusive environment, and showcasing emerging technologies and methodologies driving the field forward. Our goal is to equip attendees with practical insights and tools to accelerate the translation of research into therapies that improve patients' lives.

Apply to Speak

At A Glance
DATE:
March 18-20, 2024
LOCATION:
Hilton Boston/Woburn
2 Forbes Rd, Woburn, MA 01801
CONTACT:
Mr. Kashish Jethwani
kashish.jethwani@biogatescientificcenter.com
Reasons to Attend
By attending #ADP, you can gain new knowledge, create memorable experiences, and hear about the latest breakthroughs in antibody research and development while connecting with colleagues and top professionals from around the globe. Here are a few reasons why #ADP is an unparalleled event in the field:
NETWORKING
The conference attracts a diverse group of industry professionals, such as scientists, researchers, business leaders, and investors, providing attendees with a unique opportunity to network and connect with individuals from different areas of the industry.
KNOWLEDGE
The conference provides an opportunity to gain insights into the latest advancements, technologies, and best practices in antibody manufacturing and commercialization.
INNOVATION
Attending the conference can help individuals stay up to date with the latest trends and innovations in the industry, enabling them to explore new ideas and opportunities for growth.

WHO SHOULD ATTEND?

  •  C-Level Executives
  •  Senior Scientists
  •  Decision Makers
  •  Presidents, VPs & SVPs
  •  Researchers & Developers
  •  Healthcare professionals
  •  Academicians
  •  Manufacturers
  •  Consultants
  •  Drug developers
  •  Directors
  •  Product Developers
  •  Regulatory Specialists
  •  Principal Investigators
SESSION TRACKS
ANTIBODY DEVELOPMENT AND PRODUCTION - 2024
Track
The Science of COVID-19 Antibodies:
From Production to Immunity
In this session, you will gain insight into COVID-19 antibodies. This will cover their production process, the protection they offer against the virus, and how they can be identified through serological testing. Additionally, we will explore the present understanding of the effectiveness of COVID-19 antibodies in combating new virus variants.
Track
Double the Power:
Unleashing the Potential of Multispecific Antibodies
This session covers multispecific antibodies - engineered molecules that can bind to two different target molecules at once. It will discuss their design principles and applications in cancer immunotherapy, autoimmune diseases, and drug delivery. We will also examine the challenges and latest clinical advancements in developing multispecific antibodies. Overall, this session provides an overview of their potential as powerful medical tools.
Track
The Future of Antibody Engineering:
Opportunities and Challenges in Translational Research
This session discusses antibody engineering - designing and modifying antibodies for medical use. It covers the latest technology advancements in optimizing antibody affinity, specificity, and pharmacokinetics. We will also explore the challenges and opportunities of translating antibody engineering research into clinical practice, and its potential impact on human health.
Track
Manufacturing and Scale-up of Antibody-based Targeted Therapy Products
This session covers targeted therapy using antibodies, including their development, optimization, and clinical applications. It discusses the latest advances in the field, including novel antibody formats, and the integration of technologies like AI and gene editing. Additionally, it provides insights into the challenges and opportunities in antibody-based targeted therapies and their potential to revolutionize disease treatment.
Track
Antibodies as Diagnostic Tools:
Revolutionizing Disease Detection and Management
This session covers the latest antibody-based diagnostic technologies, including monoclonal antibodies, biosensors, and imaging modalities. It examines their advantages, limitations, and emerging trends, such as point-of-care testing and digital health technologies. Additionally, we will explore their applications in detecting infectious diseases, cancer, and autoimmune disorders. The challenges and opportunities in translating antibody-based diagnostics into clinical practice, including regulatory and commercial considerations, will also be discussed.
Track
Exploring the potential of Antibody-drug conjugates (ADCs):
From discovery to clinical applications
This session covers the rapidly evolving field of Antibody-Drug Conjugates (ADCs), including the latest advances in their discovery and development. It explores innovative approaches to linker and payload selection, pharmacokinetics, and enhancing their therapeutic index. Additionally, case studies of ADCs in clinical development will be showcased, along with the unique challenges and opportunities of this promising therapy.
Track
Current status and future prospects of immunotherapeutics
This session on Immunotherapeutics covers the use of the immune system to treat cancer, autoimmune disorders, and infectious diseases. It discusses different approaches, such as monoclonal antibodies, vaccines, checkpoint inhibitors, and CAR T-cell therapy. It also covers current research trends, challenges, and future directions in immunotherapeutic development.
Track
Commercialization strategies for antibody-based therapeutics
This session will cover the business and commercial aspects of antibodies, including market analysis, product development, regulation, intellectual property, licensing, manufacturing, and commercialization strategies. It will provide insights into challenges and opportunities for entrepreneurs, investors, and business leaders involved in antibody-based product development and commercialization.
Track
Accelerating Antibody Discovery:
Techniques, Platforms, and Strategies
This session discusses the latest advancements in antibody discovery and optimization. It covers emerging technologies and novel approaches revolutionizing the field, aimed at identifying antibodies with optimal properties such as high affinity, specificity, selectivity, and minimal immunogenicity.
Track
Monoclonal antibodies for targeted drug delivery
This session explores various applications and developments in the field of monoclonal antibodies. Topics include their use in therapeutics, diagnostics, research, and other fields. It also discusses current challenges and future opportunities in developing and applying monoclonal antibodies.
ADP2024 Keynote Speaker
Gregory Adams
Chief Scientific Officer, Elucida Oncology, Inc.
BSC SPEAKERS
Jean Ge
Patent Attorney, Wolf Greenfield., USA
David B. Weiner
Executive Vice President, The Wistar Institute
Joseph Murphy
Founder and president, ImmunePCS, LLC
Eric Fossel
CEO and Founder, Viska Bio
Michael Agrez
CEO and CSO, Inter-K Peptide Therapeutics
Adrian V. S. Hill
Director, The Jenner Institute, University of Oxford
Vanessa Elharrar
Vice President, Vaccines Business Strategy Lead, PPD
Michael Sumner
Chief Medical Officer, Inovio
Lynda Tussey
Chief Development Officer, Vaxess Technologies
Martin Moore
Founder & Chief Scientific Officer, Meissa Vaccines
Feng Xuan
Co-founder, President & CTO, Spear Bio
Angus Sinclair
Senior Vice President Immuno-Oncology, IGM Biosciences
Heinz Lubenau
Chief Executive Officer, NEC Bio Therapeutics
Bradley J. Monk
Professor, Division of Gynecologic Oncology, University of Arizona College of Medicine
Kevin P Killeen
Chief Scientific Officer, Matrivax
Joseph Joyce
Distinguished Scientist, Vaccine Process Research & Development (VPRD), Merck

REGISTER NOW

ANTIBODY DEVELOPMENT AND PRODUCTION - 2024

ACADEMIC
$450
INDUSTRY
$750
STUDENT
$150
VIRTUAL
$99

Cancellation Policy

All cancellations must be sent by email at kashish.jethwani@biogatescientificcenter.com
Cancellations received up and including November 18, 2023: full refund less a $150 towards the administrative fee.
Cancellations received between November 19 until Jaunary 21, 2024: 50% will be refunded.
Cancellations received from January 22, 2024: no refund will be made.

Group Registration
If you would like to register a team of 3 or more,
please contact: kashish.jethwani@biogatescientificcenter.com for your discount coupon code before registering

Transfer to next year
If you are unable to attend the summit at any given time, we will transfer your ticket to next year.

SPONSORSHIP DETAILS
BECOME A SPONSOR OR EXHIBITOR
ADP2024 provides the much-needed platform on which industry executives can network, connect, and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with (Event Name) will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend so that your financial and resource investment is smartly allocated.
For additional queries regarding accommodation, please contact:

Kashish Jethwani

Email: kashish.jethwani@biogatescientificcenter.com

VENUE DETAILS
ANTIBODY DEVELOPMENT AND PRODUCTION - 2024

Hilton Boston/Woburn

2 Forbes Rd, Woburn, MA 01801

We have blocked limited rooms for our attendees at the hotel. You can confirm your accommodation booking at the discounted charges through the registration page.

For additional queries regarding accommodation, please contact:

Kashish Jethwani

Email: kashish.jethwani@biogatescientificcenter.com